Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06271044
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-21
First Post:
2024-02-14
Brief Title:
a Reducing Radioiodine Treatment in Papillary Thyroid Cancer RAILESS
Sponsor:
Helsinki University Central Hospital
Organization:
Helsinki University Central Hospital
Study Overview
Official Title:
Reducing Radioiodine Treatment in Low Risk Papillary Thyroid Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study if its is safe to reduce the amount of postoperative treatments in those patients who have been operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm and in whom postoperative thyroglobulin levels are of low level
Detailed Description:
The purpose of the study to enroll about 50 patients operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm and in whom postoperative thyroglobulin levels are of low level
Methods either to follow-up patients according to the study protocol without radioiodine treatment or to give a radioiodine treatment with a dose of 11 GBq according to the normal Finnish treatment protocol for papillary thyroid cancer to those patients who themselves preferred to have a normal postoperative treatment
Methods either to follow-up patients according to the study protocol without radioiodine treatment or to give a radioiodine treatment with a dose of 11 GBq according to the normal Finnish treatment protocol for papillary thyroid cancer to those patients who themselves preferred to have a normal postoperative treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None